WO2018114784A1 - Model of reconstructed sebocyte epithelium differentiated from primary human sebocytes - Google Patents

Model of reconstructed sebocyte epithelium differentiated from primary human sebocytes Download PDF

Info

Publication number
WO2018114784A1
WO2018114784A1 PCT/EP2017/083285 EP2017083285W WO2018114784A1 WO 2018114784 A1 WO2018114784 A1 WO 2018114784A1 EP 2017083285 W EP2017083285 W EP 2017083285W WO 2018114784 A1 WO2018114784 A1 WO 2018114784A1
Authority
WO
WIPO (PCT)
Prior art keywords
sebocytes
medium
culture medium
ers
reconstructed
Prior art date
Application number
PCT/EP2017/083285
Other languages
French (fr)
Inventor
Theebah SELLATHURAI
Paulo MARHINO
Gayané Azadiguian
Martine ZANINI
Fabien GIRARD
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2018114784A1 publication Critical patent/WO2018114784A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0633—Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts

Definitions

  • the present invention relates to a model of reconstructed sebocyte epithelium.
  • Oily/dry skin disorders are often due to a malfunction of the pilosebaceous unit, including an abnormal production of sebum. Identifying solutions for these disorders entails designing biological models that are compatible with the screening of chemical or biological compounds, in particular in vitro models of sebocyte epithelium.
  • the cell line SZ95 was developed in Zouboulis et at. (1999) J. Investig. Dermatol. 113:101 1 -1020
  • the cell line SEB-1 was developed in Thiboutot et al. (2003) J. Investig. Dermatol. 120:905-914
  • the cell line SEB0662 was developed in Barrault et al. (2012) Exp. Dermatol. 21 :314-316.
  • immortalized sebocytes are genetically modified cells, which can turn out to be physiologically rather far from primary sebocytes. For example, such immortalized sebocytes partially lost their potential for differentiation.
  • the present invention therefore has for object a method, preferably in vitro, for amplifying primary sebocytes, said method comprising a step of culture, in the presence of feeder cells, of primary sebocytes, preferably human non-immortalized primary sebocytes, in a "G7F-sebo2D" culture medium comprising:
  • EGF epidermal growth factor
  • said culture medium further comprising a ROCK inhibitor.
  • Another object of the invention relates to a method, preferably in vitro, for preparing a model of reconstructed sebocyte epithelium, said method comprising the steps consisting in:
  • a) seeding, on a biomaterial for reconstructed epidermis (BPER) optionally covered with extracellular matrix protein, non-immortalized primary sebocytes in suspension in a "G7F-ERS" culture medium comprising:
  • EGF epidermal growth factor
  • step b) cultivating the sebocytes seeded in step a) in immersion on said BPER in G7F- ERS medium for 1 to 4 days;
  • step b) cultivating the sebocytes obtained in step b) at the air - liquid interface on said BPER above a "G3F-ERS" culture medium comprising:
  • EGF epidermal growth factor
  • said G3F-ERS medium further comprising linoleic acid and a PPAR agonist, for a period that is suitable for allowing the differentiation of the sebocytes and lipid synthesis,
  • the present invention also concerns a model of reconstructed sebocyte epithelium likely to be obtained by the preparation method according to the invention.
  • the present invention finally has for object a method, preferably in vitro, for screening a candidate compound for treating oily and/or glistening skin, comprising the putting into contact of said candidate compound with the model of reconstructed sebocyte epithelium according to the invention.
  • the sebocytes used and/or amplified in the context of the invention are non-immortalized primary sebocytes.
  • non-immortalized primary sebocytes here means sebocytes that have not been immortalized, regardless of the immortalization technique used, or that do not come from cell lines of immortalized sebocytes.
  • the sebocytes used and/or amplified in the context of the invention are not sebocytes of the cell line SZ95 (described in Zouboulis et al. (1999) J. Investig. Dermatol. 113:101 1 -1020), or sebocytes of the cell line SEB-1 (described in Thiboutot et al. (2003) J. Investig. Dermatol. 120:905-914), or sebocytes of the cell line SEB0662 (described in Barrault et al. (2012) Exp. Dermatol. 21 :314-316).
  • non-immortalized primary sebocytes is particularly advantageous as it makes it possible retain the potential for differentiation of the sebocytes, and in particular their capacity to synthesize a sebum equivalent in vitro that has a composition close to that of sebum in vivo, including in particular most of the major families of non-polar lipids present in the sebum in vivo.
  • the primary sebocytes used in the context of the invention are preferably human sebocytes.
  • These primary sebocytes can be obtained by any technique well known to those skilled in the art.
  • the inventors have however developed a particular technique for obtaining these sebocytes from sebaceous glands coming preferably from surgical waste.
  • the primary sebocytes used in the context of the invention are primary sebocytes, preferably non-immortalized primary human sebocytes, coming from sebaceous glands coming for example from surgical waste, such as lifting waste.
  • the primary sebocytes used in the context of the invention are obtained by a method of extraction comprising the following steps:
  • the inventors have developed a method that makes it possible to amplify non-immortalized primary sebocytes, in such a way as to retain their potential for differentiation during the preparation of the in vitro model of reconstructed sebocyte epithelium.
  • This method involves the use of a ROCK inhibitor in the presence of feeder cells in a culture medium comprising 7 factors enabling the growth of the sebocytes. This use makes it possible to retain the proliferative power of the primary sebocytes by reversibly blocking their differentiation, and thereby, to form substantial stocks of primary sebocytes.
  • the present invention thus relates to a method, preferably in vitro, for amplifying primary sebocytes, as defined in the "Sebocytes" section hereinabove, comprising a step of culture, in the presence of feeder cells, of primary sebocytes, as defined in the "Sebocytes” section hereinabove, preferably non-immortalized primary sebocytes, in particular non-immortalized primary human sebocytes, in a "G7F-sebo2D" culture medium comprising:
  • EGF epidermal growth factor
  • hydrocortisone hydrocortisone
  • said culture medium further comprising a ROCK inhibitor.
  • amplification here means the proliferation or multiplication of cells.
  • the cultivated primary sebocytes are non-immortalized primary human sebocytes, preferably coming from sebaceous glands coming for example from surgical waste, such as lifting waste.
  • the cultivated primary sebocytes come from the method of extraction defined in the "Sebocytes" section hereinabove.
  • the method of amplification according to the invention comprises, before the step of culture, a step of extracting sebocytes, in particular from surgical waste, implementing the method of extraction defined in the "Sebocytes" section hereinabove.
  • feeder cell here means cells used in culture with other types of cells and which assist in the growth thereof. Feeder cells have their growth stopped, for example by irradiation, but are viable and form a substrate whereon the other cells can grow.
  • the feeder cells are fibroblasts, such as fibroblasts from fibroblast lines, for example 3T3 fibroblasts, and most preferably irradiated 3T3 fibroblasts, also called 3T3i.
  • the "G7F-sebo2D" culture medium used in the method of amplification according to the invention is a nutrient medium comprising a base medium and the 7 following factors that allow for the growth of the sebocytes:
  • EGF epidermal growth factor
  • the base medium can in particular be a DMEM medium, DMEM/F12, MEM, RPMI medium, William's medium, KGM medium, dermalife-K medium, keratinocyte-SFM medium, or Glasgow medium.
  • the base medium is DMEM/F12 medium.
  • the base medium further contains L-glutamine, preferably at a concentration of 0.5 to 20 mM, more preferably at a concentration of 2 to 10 mM, still preferably at a concentration of 4 to 5 mM.
  • the base medium further comprises fetal calf serum, preferably at a concentration from 5 to 20%, and more preferably at a concentration of 10%.
  • the "G7F-sebo2D” culture medium may further comprise antibiotics.
  • the “G7F-sebo2D” culture medium comprises the following 7 factors that allow for sebocyte growth:
  • adenine hydrochloride preferably at a concentration from 1 x10 ⁇ 4 M to 2x10 "4 M, in particular at a concentration from 1 .4x10 "4 to 1 .9x10 "4 M, more particularly from 1 .5x10 "4 to 1 .8x10 “4 M or from 1 .6x10 "4 to 1 .7x10 "4 M,
  • epidermal growth factor for example recombinant human EGF, preferably at a concentration from 5 to 25 ng/ml, in particular at a concentration from 7 to 20 ng/ml, more particularly from 8 to 15 ng/ml, and more particularly from 9 to 12 ng/ml or from 10 to 1 1 ng/ml,
  • hydrocortisone for example hydrocortisone 21 -hemisuccinate sodium, preferably at a concentration from 0.1 to 1 ⁇ g/ml, in particular at a concentration from 0.2 to 0.9 ⁇ g/ml, more particularly from 0.3 to 0.8 ⁇ g/ml, from 0.4 to 0.7 ⁇ g/ml or from 0.5 to 0.6 ⁇ g/m ⁇ ,
  • insulin for example recombinant human insulin, preferably at a concentration from 1 to 10 ⁇ g/ml, in particular at a concentration from 2 to 9 ⁇ g/ml, more particularly from 3 to 8 ⁇ g/ml, from 4 to 7 ⁇ g/ml or from 5 to 6 ⁇ g/ml,
  • isoproterenol also called isoprenaline
  • isoprenaline for example (-)-isoproterenol hydrochloride
  • a concentration from 5x10 "7 to 5x10 "6 M in particular at a concentration from 6x10 "7 to 4x10 "6 M, more particularly from 7x10 "7 to 3x10 "6 M, from 8x10 "7 to 2x10 "6 M or from 9x10 "7 to 1 x10 "6 M,
  • transferrin also called siderophilin
  • human transferrin for example human apo-transferrin
  • a concentration from 1 to 10 ⁇ g/ml in particular at a concentration from 2 to 9 ⁇ g/ml, more particularly from 3 to 8 ⁇ g/ml, from 4 to 7 ⁇ g/ml or from 5 to 6 ⁇ g/ml
  • transferrin also called siderophilin
  • human transferrin for example human apo-transferrin
  • triiodothyronine also called 3,3',5-triiodo-L-thyronine or T 3
  • T 3 triiodothyronine
  • triiodothyronine sodium preferably at a concentration from 1 x10 ⁇ 9 to 5x10 "9 M, in particular at a concentration from 1 .5x10 "9 to 4x10 "9 M, more particularly from 1 .75x10 "9 to 3x10 "9 M or from 2x10 "9 to 2.5x10 "9 M.
  • the "G7F-sebo2D" culture medium comprises:
  • transferrin preferably human transferrin
  • the "G7F-sebo2D" culture medium comprises:
  • transferrin preferably human transferrin
  • the "G7F-sebo2D" culture medium further comprises a ROCK inhibitor.
  • ROCK inhibitor here means a protein, a nucleic acid, a small molecule, an antibody or another agent that prevents the expression of ROCK or decreases the activity of ROCK such as its kinase activity.
  • ROCK inhibitors are well known to those skilled in the art and include the compound Y-27632 and the compounds H-1 152, Y- 30141 , Wf-536, HA-1077, hydroxyl-HA-1077, GSK269962A and SB-772077-B.
  • the ROCK inhibitor is the compound Y-27632.
  • the ROCK inhibitor in particular the compound Y-27632, is preferably added to the "G7F-sebo2D" culture medium at a concentration from 5 to 15 ⁇ , preferably from 6 to 14 ⁇ , more preferably from 7 to 13 ⁇ , from 8 to 12 ⁇ , from 9 to 1 1 ⁇ , and most preferably at a concentration of 10 ⁇ .
  • the culture medium is preferably changed regularly during the culture of the sebocytes, for example every 1 , 2 or 3 days.
  • the primary sebocytes thereby amplified can be trypsinized and re-seeded as soon as a high level of confluence is obtained, for example a level of confluence of 70%.
  • Method for preparing a model of reconstructed sebocyte epithelium As indicated hereinabove, the inventors have furthermore developed a method for preparing a model of reconstructed sebocyte epithelium that implements non-immortalized primary sebocytes that makes it possible to obtain a three-dimensional model that is physiologically more pertinent with respect to the models described until now.
  • Another object of the invention thus relates to a method, preferably in vitro, for preparing a model of reconstructed sebocyte epithelium that comprises the steps consisting in:
  • a) seeding, on a biomaterial for reconstructed epidermis (BPER) optionally covered with extracellular matrix protein, non-immortalized primary sebocytes in suspension in a "G7F-ERS" culture medium comprising:
  • EGF epidermal growth factor
  • step b) cultivating the sebocytes seeded in step a) in immersion on said BPER in G7F- ERS medium for 1 to 4 days;
  • step b) cultivating the sebocytes obtained in step b) at the air - liquid interface on said BPER above a "G3F-ERS" culture medium comprising:
  • EGF epidermal growth factor
  • said G3F-ERS medium further comprising linoleic acid and a PPAR agonist, for a period that is suitable for allowing the differentiation of the sebocytes and lipid synthesis,
  • biomaterial for reconstructed epidermis or "BPER” here means a dermal equivalent, used as a support and integrating ingredients that are naturally present in the dermis.
  • the BPER is a matrix of collagen, in particular of type I and/or IV collagens.
  • the BPER is covered with extracellular matrix protein.
  • Extracellular matrix proteins are well known to those skilled in the art and include collagen, such as type IV or type VII collagen, fibronectin and laminin.
  • collagen such as type IV or type VII collagen
  • fibronectin preferably, the BPER is covered with fibronectin, in particular human fibronectin.
  • the non-immortalized primary sebocytes seeded in step a) are as defined in the "Sebocytes" section hereinabove.
  • these are non-immortalized primary human sebocytes, preferably pre-amplified by the method of amplification as defined in the "Method of amplification” section hereinabove but in the absence of ROCK inhibitor.
  • the method of preparation according to the invention comprises, before the step a) of seeding, a step pre-a) of pre-amplifying the non-immortalized primary sebocytes, preferably implementing the method of amplification as defined in the "Method of amplification” section hereinabove but in the absence of a ROCK inhibitor, in other words in the "G7F-Sebo2D" culture medium, as defined in the "Method of amplification” section, that does not contain any ROCK inhibitor.
  • the "G7F-ERS" culture medium used in the method of preparation according to the invention is a nutrient medium comprising a base medium and the 7 following factors that allow for the growth of the sebocytes:
  • EGF epidermal growth factor
  • the base medium can in particular be a DMEM medium, DMEM/F12, MEM, RPMI medium, William's medium, KGM medium, dermalife-K medium, keratinocyte-SFM medium or Glasgow medium.
  • the base medium is DMEM/F12 medium.
  • the base medium further contains L-glutamine, preferably at a concentration of 0.5 to 20 mM, more preferably at a concentration of 2 to 10 mM, more preferably at a concentration of 4 to 5 mM.
  • the base medium further comprises fetal calf serum, preferably at a concentration from 5 to 20%, and more preferably at a concentration of 10%.
  • the "G7F-ERS" culture medium may further comprise antibiotics, sodium pyruvate preferably at a concentration of 0.1 to 10 mM, non-essential amino acids such as those contained in the MEM Non-Essential Amino Acids Solution (100X) product commercialized by Gibco under the reference 1 1 140, in particular diluted 100 times.
  • antibiotics sodium pyruvate preferably at a concentration of 0.1 to 10 mM
  • non-essential amino acids such as those contained in the MEM Non-Essential Amino Acids Solution (100X) product commercialized by Gibco under the reference 1 1 140, in particular diluted 100 times.
  • the “G7F-ERS” culture medium comprises the following 7 factors that allow for sebocyte growth:
  • adenine hydrochloride preferably at a concentration from 1 x10 ⁇ 4 M to 2x10 "4 M, in particular at a concentration from 1 .4x10 "4 to 1 .9x10 "4 M, more preferably from 1 .5x10 "4 to 1 .8x10 "4 M or from 1 .6x10 "4 to 1 .7x10 "4 M,
  • epidermal growth factor (EGF) for example recombinant human EGF, preferably at a concentration from 30 to 75 ng/ml, in particular at a concentration from 35 to 70 ng/ml, more preferably from 40 to 65 ng/ml, 45 to 60 ng/ml or from 50 to 55 ng/ml,
  • hydrocortisone for example hydrocortisone 21 -hemisuccinate sodium, preferably at a concentration from 0.1 to 1 ⁇ g/ml, in particular at a concentration from 0.2 to 0.9 ⁇ g/ml, more preferably from 0.3 to 0.8 ⁇ g/ml, from 0.4 to 0.7 ⁇ g/ml or from 0.5 to 0.6 Mg ml,
  • insulin for example recombinant human insulin, preferably at a concentration from 1 to 10 ⁇ g/ml, in particular at a concentration from 2 to 9 ⁇ g/ml, more preferably from 3 to 8 ⁇ g/ml, from 4 to 7 ⁇ g/ml or from 5 to 6 ⁇ g/ml,
  • isoproterenol also called isoprenaline
  • isoprenaline for example (-)-isoproterenol hydrochloride
  • a concentration from 5x10 "7 to 5x10 "6 M in particular at a concentration from 6x10 "7 to 4x10 "6 M, more preferably from 7x10 "7 to 3x10 "6 M, from 8x10 "7 to 2x10 "6 M or from 9x10 "7 to 1 x10 "6 M,
  • transferrin also called siderophilin
  • human transferrin for example human apo-transferrin
  • a concentration from 1 to 10 ⁇ g/ml in particular at a concentration from 2 to 9 ⁇ g/ml, more preferably from 3 to 8 ⁇ g/ml, from 4 to 7 ⁇ g/ml or from 5 to 6 ⁇ g/ml
  • transferrin also called siderophilin
  • human transferrin for example human apo-transferrin
  • triiodothyronine also called 3,3',5-triiodo-L-thyronine or T 3
  • T 3 triiodothyronine
  • triiodothyronine sodium preferably at a concentration from 1 x10 ⁇ 9 to 5x10 "9 M, in particular at a concentration from 1 .5x10 "9 to 4x10 "9 M, more preferably from 1 .75x10 "9 to 3x10 "9 M or from 2x10 "9 to 2.5x10 "9 M.
  • the "G7F-ERS" culture medium comprises:
  • transferrin preferably human transferrin
  • the "G7F-ERS" culture medium comprises:
  • transferrin preferably human transferrin
  • the sebocytes are advantageously cultivated in immersion in the G7F-ERS medium, as defined hereinabove, for 1 to 4 days, preferably for 3 days.
  • the G7F-ERS culture medium can be replaced regularly, for example every day or every 2 days.
  • This step of culture allows for the proliferation of the sebocytes.
  • step b) of culture in immersion is followed by a step c) of culture of sebocytes at the air - liquid interface on the BPER above a "G3F-ERS" culture medium comprising:
  • EGF epidermal growth factor
  • the "G3F-ERS" culture medium used in the method of preparation according to the invention is a nutrient medium comprising a base medium and the 3 following factors that allow for the growth and/or differentiation of the sebocytes:
  • EGF epidermal growth factor
  • the base medium can in particular be DMEM medium, DMEM/F12, MEM, RPMI medium, William's medium, KGM medium, dermalife-K medium, keratinocyte-SFM medium or Glasgow medium.
  • the base medium is DMEM/F12 medium.
  • the base medium further contains L-glutamine, preferably at a concentration of 0.5 to 20 mM, more preferably at a concentration of 2 to 10 mM, still preferably at a concentration of 4 to 5 mM.
  • the base medium further comprises fetal calf serum, preferably at a concentration from 5 to 20%, more preferably at a concentration of 10%.
  • the “G3F-ERS” culture medium comprises the following 3 factors that allow for sebocyte growth and/or differentiation:
  • epidermal growth factor for example recombinant human EGF, preferably at a concentration from 30 to 75 ng/ml, in particular at a concentration from 35 to 70 ng/ml, from 40 to 65 ng/ml, 45 to 60 ng/ml or from 50 to 55 ng/ml
  • hydrocortisone for example hydrocortisone 21 -hemisuccinate sodium, preferably at a concentration from 0.1 to 1 ⁇ g/ml, in particular at a concentration from 0.2 to 0.9 ⁇ g/ml, from 0.3 to 0.8 ⁇ g/ml, from 0.4 to 0.7 ⁇ g/ml or from 0.5 to 0.6 ⁇ g/ml, and
  • insulin for example recombinant human insulin, preferably at a concentration from 1 to 10 ⁇ g/ml, in particular at a concentration from 2 to 9 ⁇ g/ml, from 3 to 8 ⁇ g/ml, from 4 to 7 ⁇ g/ml or from 5 to 6 ⁇ 9 ⁇ .
  • the "G3F-ERS” medium thus has the particularity of comprising only 3 factors that allow for sebocyte growth and/or differentiation.
  • the "G3F-ERS” medium is devoid of adenine hydrochloride, isoproterenol, human transferrin and/or triiodothyronine.
  • the "G3F-ERS" culture medium comprises:
  • the "G3F-ERS" culture medium comprises:
  • the "G3F-ERS" medium can furthermore comprise vitamin C, preferably at a concentration from 0.05 to 0.5 mg/ml, in particular at a concentration from 0.06 to 0.4 mg/ml, from 0.07 to 0.3 mg/ml, from 0.08 to 0.2 mg/ml or from 0.09 to 0.1 mg/ml.
  • the "G3F-ERS” medium can further comprise antibiotics, sodium pyruvate preferably at a concentration of 0.1 to 10 mM, non-essential amino acids such as those contained in the MEM Non-Essential Amino Acids Solution (100X) product commercialized by Gibco under the reference 1 1 140, in particular diluted 100 times.
  • antibiotics sodium pyruvate preferably at a concentration of 0.1 to 10 mM
  • non-essential amino acids such as those contained in the MEM Non-Essential Amino Acids Solution (100X) product commercialized by Gibco under the reference 1 1 140, in particular diluted 100 times.
  • the "G3F-ERS" medium as defined hereinabove further comprises linoleic acid and a PPAR agonist.
  • the "G3F-ERS" medium comprises several PPAR agonists, in particular at least two PPAR agonists, preferably at least three PPAR agonists.
  • PPAR peroxisome proliferator-activated receptor
  • PPAR peroxisome proliferator-activated receptor
  • PPAR peroxisome proliferator-activated receptor
  • alpha alpha
  • gamma alpha
  • delta delta
  • PPAR is structured in four separate regions.
  • An N-terminal domain has a transactivating function independent of the ligand (AF-1 ).
  • the DNA binding domain or DBD is constituted of two zinc fingers characteristic of the superfamily of nuclear receptors.
  • PPAR has a hinge region preceding the ligand binding domain or LBD that has a transactivating function dependent of the ligand (AF-2).
  • the PPAR agonist used in the context of the invention can be a pan-PPAR agonist (i.e. an inducer of the three types of PPAR, alpha, gamma and beta/delta), a selective PPAR-alpha agonist and/or a selective PPAR-delta agonist and/or a selective PPAR- gamma agonist.
  • a pan-PPAR agonist i.e. an inducer of the three types of PPAR, alpha, gamma and beta/delta
  • a selective PPAR-alpha agonist and/or a selective PPAR-delta agonist and/or a selective PPAR- gamma agonist i.e. an inducer of the three types of PPAR, alpha, gamma and beta/delta
  • PPAR agonists are well known to those skilled in the art and include, as a pan-PPAR agonist, aleglitazar, muraglitazar, saroglitazar and tesaglitazar, as a selective PPAR-delta agonist, the compound GW501516 ( ⁇ 4-[( ⁇ 4-methyl-2-[4- (trifluoromethyl)phenyl]-1 ,3-thiazol-5-yl ⁇ methyl)sulfanyl]-2-methylphenoxy ⁇ acetic acid), and the compound GW0742 ([4-[[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5- thiazolyl]methyl]thio]-2-methylphenoxy]-acetic acid) referenced as CAS [317318-84-6], as a PPAR-alpha agonist, derivatives of fibric acid such as aluminum cofibrate, beclobrate, bezafibrate, binifibrate, cip
  • the PPAR agonist used in the context of the invention is the compound GW0742.
  • the "G3F-ERS" medium contains only one PPAR agonist, preferably the PPAR agonist is the compound GW0742.
  • the "G3F-ERS" medium comprises from 1 x10 ⁇ 7 to 2.5x10 "5 M of linoleic acid, preferably from 5x10 "7 to 2x10 "5 M, from 1 x10 ⁇ 6 to 1 .5x10 "5 M, from 5x10 "6 to 1 x10 "5 M, or from 9x10 "6 to 1 x10 "5 M.
  • the "G3F-ERS" medium comprises from 1 x10 ⁇ 6 to 5x10 "6 M of a PPAR agonist, in particular of compound GW0742, preferably from 1 .5x10 "6 to 4x10 "6 M, from 2x10 "6 to 3.5x10 "6 M or from 2.5x10 "6 to 3x10 "6 M.
  • the "G3F-ERS” medium comprises from 5x10 "6 to 2.5x10 "5 M of linoleic acid and from 1 x10 ⁇ 6 to 5x10 "6 M of a PPAR agonist, said PPAR agonist being preferably the compound GW0742.
  • the "G3F-ERS” medium comprises from 8x10 "6 to 2x10 "5 M of linoleic acid and from 2x10 "6 to 5x10 "6 M of a PPAR agonist, said PPAR agonist being preferably the compound GW0742.
  • phase c) of culture at the air-liquid interface that the sebocytes differentiate and produce a mixture of neutral lipids (such as glycerides, cholesterol, esters of cholesterol and free fatty acids).
  • neutral lipids such as glycerides, cholesterol, esters of cholesterol and free fatty acids.
  • the step c) of culture at the air-liquid interface is implemented during a suitable duration for allowing the differentiation of sebocytes and lipid synthesis.
  • the step c) of culture at the air-liquid interface is implemented for 5 to 25 days, preferably for 7 to 20 days, for 8 to 17 days or for 10 to 15 days.
  • step c) of culture at the air-liquid interface can be continued once the sebocytes are differentiated, for example in order to use the obtained model in screening tests.
  • the G3F-ERS culture medium can be replaced regularly, partially or entirely, for example every day, every 2 days or every 3 days.
  • the model of reconstructed sebocyte epithelium is obtained at the end of step c).
  • This model is different from the models of sebocyte epithelium of the state of the art by the fact that the sebocytes that form it are not immortalized and that its histology is very close to that of the in vivo sebaceous gland.
  • almost all of the large families of non-polar lipids (glycerides, cholesterol, fatty acids, esters of cholesterol) present in the sebum are present in the model of reconstructed sebocyte epithelium obtained by the preparation method according to the invention
  • the present invention therefore also concerns a model of reconstructed sebocyte epithelium likely to be obtained by the preparation method according to the invention.
  • the inventors have shown that the lipid synthesis of the model of reconstructed sebocyte epithelium according to the invention could be modulated using compounds known for modulating this activity in vivo such as 13-cis-retinoic acid.
  • the model of reconstructed sebocyte epithelium according to the invention can therefore be used to identify compounds that modulate the lipid synthesis of sebocytes.
  • the present invention thus relates to a method, preferably in vitro, for screening compounds that modulate the lipid synthesis of sebocytes, comprising putting into contact a candidate compound with the model of reconstructed sebocyte epithelium according to the invention.
  • the present invention also has for object a method, preferably in vitro, for screening compounds for treating oily and/or glistening skin, comprising putting into contact a candidate compound with the model of reconstructed sebocyte epithelium according to the invention.
  • the screening methods according to the invention can further comprise a step of analyzing lipids synthesized by the sebocytes of the model of reconstructed sebocyte epithelium in the presence of the candidate compound, for example by labeling neutral lipids, for example with BODIPY, Lipidtox or oil-red-o.
  • BODIPY labeling neutral lipids
  • Lipidtox Lipidtox or oil-red-o.
  • Figure 1 Scheme of extraction of primary human sebocytes obtained from a biopsy.
  • FIG. 2 Observations under the microscope of sebocytes extracted from sebaceous glands after 6 days of culture on plastic.
  • Part A culture in G7F-sebo2D medium
  • Part B culture in G7F-sebo2D medium in the presence of a ROCK inhibitor (Y27632).
  • Figure 3 A: Example of a histological section of an in vivo sebaceous gland adapted from Woldow et al. (2009) Dermatology Online Journal 15:14.
  • B Scheme representing an in vivo sebaceous gland adapted from Niemann et al. (2012) Seminars in Cell & Developmental Biology 23:928-936.
  • Figure 4 Left part: Examples of histological sections of the model of reconstructed sebocyte epithelium according to the invention at D13 colored with HES.
  • NC non-treated control
  • DMSO solvent DMSO
  • Example 1 Extraction of primary human sebocytes obtained from a biopsy
  • This example describes the extraction of primary human sebocytes carried out by using the extraction protocol according to the invention.
  • Pieces of lifting comprising hairs were used.
  • the pieces of lifting were selected and placed in a Petri dish containing PBS.
  • the surface of the skin was shaved using a scalpel in order to remove the hair.
  • the pieces were then cut into pieces of about 0.5 cm 2 and placed in a bath of antibiotics (medium with 10% antibiotics) for 20 min.
  • 3T3i irradiated fibroblasts were defrosted and seeded in the "G7F-sebo2D" medium comprising 10 ⁇ of Y-27632.
  • the pieces of skin were covered with an aqueous solution of Dispase II at 2.4 U/ml, and incubated at 4°C overnight or 2h at 37°C.
  • the dispase was then removed, the pieces rinsed in PBS, and the epidermis was separated from the dermis by using microdissection tweezers. The dermis was eliminated. The sebaceous gland of each hair follicle found under the epidermis was removed and deposited into a well comprising "G7F-sebo2D" medium.
  • Antibiotics-antimycotics 1 % Gibco n° 15240-062
  • the medium comprising the glands was then recovered and centrifuged 8 min at 190 g. The supernatant was eliminated and the glands were resuspended in trypsin. After 5 to 10 min of incubation, the tubes were vortexed in order to dissociate the glands. The trypsin was then inhibited by adding "G7F-sebo2D" medium supplemented with antibiotics.
  • the whole was then centrifuged for 8 min at 190 g and the pellet was resuspended.
  • the cells were counted with trypan blue then seeded on the fibroblasts in culture in "G7F-sebo2D" medium supplemented with antibiotics and comprising 10 ⁇ of Y-27632.
  • Example 2 Method for amplifying non-immortalized human sebocytes
  • This example describes the amplification of primary human sebocytes carried out by using the method of amplification according to the invention.
  • the non-immortalized primary human sebocytes were put into suspension in G7F- sebo2D medium + Y27632, and seeded on the fibroblasts at a rate of 2,400 cells / cm 2 .
  • the culture medium was changed every 48h.
  • Figure 2 shows microscopic observations of sebocytes after 6 days of culture on plastic in G7F-sebo2D medium supplemented with antibiotics with and without Y27632.
  • Example 3 Method for preparing a model of reconstructed sebocyte epithelium.
  • This example describes the preparation of a model of reconstructed sebocyte epithelium from non-immortalized primary human sebocytes using the method of preparation according to the invention.
  • the BPERs comprising type I and type IV collagen were rinsed twice in PBS and once in DMEM/F12 Glutamax 3:1 base medium + antibiotics.
  • the BPERs were then coated with fibronectin the day before inoculation of sebocytes.
  • the 3T3i fibroblasts and the sebocytes were either co-seeded, or seeded sequentially, the sebocytes then being seeded at least 2h after the fibroblasts.
  • Antibiotics-antimycotics 1 % Gibco no. 15240-062
  • the flask comprising the cells was incubated at 37°C with 5% of C0 2 for 6 days, changing the medium every two days.
  • G7F-ERS medium supplemented with L-glutamine, sodium pyruvate, nonessential amino acids, fetal bovine serum and antibiotics, was deposited under BPER inserts.
  • the amplified sebocytes were trypsinized, centrifuged at 190 g and resuspended in supplemented "G7F-ERS" medium in such a way as to obtain a suspension at 0.8.10 6 cells/ml.
  • G3F-ERS medium supplemented with L-glutamine, sodium pyruvate, nonessential amino acids, fetal bovine serum, antibiotics, vitamin C, linoleic acid and GW0742, was deposited under each insert.
  • composition of the G3F-ERS medium for a final volume of 500 ml Composition of the G3F-ERS medium for a final volume of 500 ml:
  • the sebocytes differentiate and produce a mixture of neutral lipids (glycerides, cholesterol, esters of cholesterol, free fatty acids).
  • Figure 4 shows histological sections of the model obtained at the end of this protocol, compared to an Episkin epidermis model (referenced EPISKIN/L/13 by EPISKIN S.A.) and to an in vivo sebaceous gland (Figure 3).
  • Example 4 Study of the modulation of the synthesis of the neutral lipids by different molecules in a model of reconstructed sebocyte epithelium according to the invention
  • This example shows that the lipid synthesis of the model of reconstructed sebocyte epithelium according to the invention can be modulated by using compounds known to modulate this activity in vivo such as 13-cis-retinoic acid and that the model of reconstructed sebocyte epithelium according to the invention can therefore be used to identify compounds that modulate the lipid synthesis of sebocytes.
  • BODIPY® (493/503) is a fluorochrome that has a particular affinity for neutral lipids.
  • This labeling is carried out on sections of 10 ⁇ thick obtained from cryomicrotom sections of samples frozen at OCT (Optimal Cutting Temperature).
  • Bodipy preparation at 25 ⁇ g/ml (dilution to 1/40 of aliquots prepared beforehand at 1 mg/ml DMSO), 250 ⁇ Bodipy 1 mg/ml + 9750 ⁇ PBS + -Goat serum.
  • the acquisition of the fluorescence images is carried out under standardized conditions (exposure time, white-black settings...) and with a magnification that makes it possible to visualize the epithelium over its entire thickness.
  • the images were acquired in fluorescence with a Zeiss Axioplan 2 imaging microscope combined with a Zeiss AxioCam MRm camera, and with the Zeiss ZEN lite image acquisition software. Images are recorded in a format that is compatible with the image analysis software and with the scale of the sizes.
  • IMAGEJ Analysis of images is carried out with IMAGEJ: the labelling is thus selected, and the labeled surface is measured for each sample.
  • this analysis is conducted over several fields per histological section, and over several histological sections per biological sample. For each sample the measurements are averaged, and for each test condition the average of the replicates per treatment condition is taken.
  • results can be standardized with respect to the untreated control in order to be able to express a significance over all of the tests conducted.
  • Figure 4 shows the results obtained by labeling with BODIPY and image analysis with IMAGEJ.
  • the surface results were obtained by compiling 3 different studies after standardizing values with respect to the untreated controls. All of the compounds tested being solubilized in DMSO, a solvent control was integrated into each study. Isotretinoin was used as a pharmaceutical reference or positive control for the functionality of the model, and made it possible to validate the studies. 3 cosmetic compounds were evaluated in parallel (compounds A, B and C).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the amplification of non-immortalized primary sebocytes by culture in a specific culture medium comprising 7 factors allowing for the growth of sebocytes and a ROCK inhibitor, and the production of a model of reconstructed sebocyte epithelium in 3 dimensions on an extracellular matrix support with a culture phase at the air-liquid interface, then the adding of an inducing mixture in order to optimize the differentiation into mature sebocytes loaded with non-polar lipids, this mixture comprising linoleic acid as a precursor and a PPAR agonist, in a culture medium comprising only 3 factors allowing for the growth and/or the differentiation of sebocytes, of which EGF at a high concentration.

Description

Model of reconstructed sebocyte epithelium differentiated from primary human sebocytes
The present invention relates to a model of reconstructed sebocyte epithelium.
Oily/dry skin disorders are often due to a malfunction of the pilosebaceous unit, including an abnormal production of sebum. Identifying solutions for these disorders entails designing biological models that are compatible with the screening of chemical or biological compounds, in particular in vitro models of sebocyte epithelium.
However, because of their in vivo function, primary sebocytes tend in vitro to differentiate rapidly through the accumulation of lipid droplets and finally degenerate, which renders the culture and the amplification thereof, although indispensable for obtaining a quantity of biological material that is sufficient for preparing models of reconstructed sebocyte epithelium, very difficult in vitro and therefore limits the use thereof in the framework of the screening of agents.
The most commonly used technique in literature to circumvent this problem of sebocyte differentiation is the immortalization thereof or the generation of cell lines. As such, the cell line SZ95 was developed in Zouboulis et at. (1999) J. Investig. Dermatol. 113:101 1 -1020, the cell line SEB-1 was developed in Thiboutot et al. (2003) J. Investig. Dermatol. 120:905-914 and the cell line SEB0662 was developed in Barrault et al. (2012) Exp. Dermatol. 21 :314-316. These are the cell lines that have been used until now for producing cell models.
However, immortalized sebocytes are genetically modified cells, which can turn out to be physiologically rather far from primary sebocytes. For example, such immortalized sebocytes partially lost their potential for differentiation.
Moreover, most of the work of modeling the sebaceous function has been carried out until now using cell models cultivated in 2 dimensions, in particular using immortalized cell lines SZ95 and SEB-1 . Currently, very few studies have shown the production of cell models in 3 dimensions. Mention can however be made of the article Guy et al. (1996) J. Investig. Dermatol. 106:454-460 which describes models of survival glands, the article Yoshida et al. (2013) Biochem. Biophys. Res. Com. 438:640-646 which describes micro- tissues manufactured with immortalized sebocytes and the articles Barrault et al. (2012) Exp. Dermatol. 21 :314-316 and Lo Celso et al. (2008) Stem Cells 26:1241 -1252 which describe reconstructed epitheliums from immortalized sebocytes. However, these three types of models have substantial disadvantages. Indeed, in the survival gland model, the preparation of models is highly limited by the supply of survival glands and the models obtained have a large intra- and inter-donor variability. For the two other types of models, the use of cell lines and therefore of genetically modified cells is not very physiological.
There is therefore a substantial need for new methods for preparing in vitro models of reconstructed sebocyte epithelium, implementing cells that are as close as possible to cells of the sebaceous gland in vivo, while still being available in a sufficient quantity and which makes it possible to produce a 3D model with differentiated sebocytes loaded with non-polar lipids of which the lipid metabolism is as close as possible to that of the sebaceous gland in vivo.
There is also a need to obtain an in vitro model of reconstructed sebocyte epithelium of which the lifetime is sufficient for studying over time the modulation of its lipid synthesis, and therefore for screening new molecules.
The present invention results from the combination by the inventors of innovative technical solutions:
- the amplification of non-immortalized primary sebocytes by culture in a specific culture medium comprising 7 factors allowing for the growth of sebocytes and a ROCK inhibitor, in such a way as to obtain a sufficient stock of sebocytes without requiring the immortalization thereof, which makes it possible to retain their potential for differentiation, - the culture of a model of reconstructed sebocyte epithelium in 3 dimensions on an extracellular matrix support with a culture phase at the air-liquid interface, and the adding of an inducing mixture in order to optimize the differentiation in mature sebocytes loaded with non-polar lipids, this mixture comprising linoleic acid as a precursor and a PPAR agonist, in a culture medium comprising only 3 factors allowing for the growth and/or the differentiation of the sebocytes, of which EGF at a high concentration, which makes it possible to push the sebocytes to differentiate themselves and produce a mixture of non-polar lipids approaching the composition of the sebum and obtaining a model that can be cultivated up to 17 days, allowing for a usage window that is longer than the models of the state of the art. The present invention therefore has for object a method, preferably in vitro, for amplifying primary sebocytes, said method comprising a step of culture, in the presence of feeder cells, of primary sebocytes, preferably human non-immortalized primary sebocytes, in a "G7F-sebo2D" culture medium comprising:
(i) adenine hydrochloride,
(ii) epidermal growth factor (EGF),
(iii) hydrocortisone, (iv) insulin,
(v) isoproterenol,
(vi) transferrin, and
(vii) triiodothyronine,
said culture medium further comprising a ROCK inhibitor.
Another object of the invention relates to a method, preferably in vitro, for preparing a model of reconstructed sebocyte epithelium, said method comprising the steps consisting in:
a) seeding, on a biomaterial for reconstructed epidermis (BPER) optionally covered with extracellular matrix protein, non-immortalized primary sebocytes in suspension in a "G7F-ERS" culture medium comprising:
(i) adenine hydrochloride,
(ii) epidermal growth factor (EGF),
(iii) hydrocortisone,
(iv) insulin,
(v) isoproterenol,
(vi) transferrin, and
(vii) triiodothyronine;
b) cultivating the sebocytes seeded in step a) in immersion on said BPER in G7F- ERS medium for 1 to 4 days;
c) cultivating the sebocytes obtained in step b) at the air - liquid interface on said BPER above a "G3F-ERS" culture medium comprising:
(I) epidermal growth factor (EGF),
(II) hydrocortisone, and
(III) insulin,
said G3F-ERS medium further comprising linoleic acid and a PPAR agonist, for a period that is suitable for allowing the differentiation of the sebocytes and lipid synthesis,
said model of reconstructed sebocyte epithelium being obtained at the end of step c).
The present invention also concerns a model of reconstructed sebocyte epithelium likely to be obtained by the preparation method according to the invention.
The present invention finally has for object a method, preferably in vitro, for screening a candidate compound for treating oily and/or glistening skin, comprising the putting into contact of said candidate compound with the model of reconstructed sebocyte epithelium according to the invention. Detailed description of the invention
Sebocytes
Preferably, the sebocytes used and/or amplified in the context of the invention are non-immortalized primary sebocytes.
The term "non-immortalized primary sebocytes" here means sebocytes that have not been immortalized, regardless of the immortalization technique used, or that do not come from cell lines of immortalized sebocytes. In particular, the sebocytes used and/or amplified in the context of the invention are not sebocytes of the cell line SZ95 (described in Zouboulis et al. (1999) J. Investig. Dermatol. 113:101 1 -1020), or sebocytes of the cell line SEB-1 (described in Thiboutot et al. (2003) J. Investig. Dermatol. 120:905-914), or sebocytes of the cell line SEB0662 (described in Barrault et al. (2012) Exp. Dermatol. 21 :314-316).
Using non-immortalized primary sebocytes is particularly advantageous as it makes it possible retain the potential for differentiation of the sebocytes, and in particular their capacity to synthesize a sebum equivalent in vitro that has a composition close to that of sebum in vivo, including in particular most of the major families of non-polar lipids present in the sebum in vivo.
The primary sebocytes used in the context of the invention are preferably human sebocytes.
These primary sebocytes can be obtained by any technique well known to those skilled in the art. The inventors have however developed a particular technique for obtaining these sebocytes from sebaceous glands coming preferably from surgical waste.
As such in a particular embodiment, the primary sebocytes used in the context of the invention are primary sebocytes, preferably non-immortalized primary human sebocytes, coming from sebaceous glands coming for example from surgical waste, such as lifting waste.
Preferably, the primary sebocytes used in the context of the invention are obtained by a method of extraction comprising the following steps:
1 ) recovering a piece of skin, such as a piece of lifting, and optionally removing the hair from the surface of the skin,
2) optionally cutting the piece of skin into pieces of about 0.5 cm2 in surface area, and treating them with antibiotics, for example in a culture medium such as the DMEM medium, preferably for 15 to 30 min, typically for 20 min, 3) covering the pieces of skin with dispase, preferably with dispase II, and incubating them for a suitable duration so that the dermis can then be separated from the epidermis via microdissection, for example by incubating them for one night at 4°C, or for 2 h at 37°C,
4) rinsing the pieces of skin and placing them in a "G7F-sebo2D" culture medium as defined hereinbelow,
5) separating the epidermis from the dermis of the piece of skin by microdissection and storing the sampled epidermis,
6) sampling the sebaceous glands of the hair follicles present under the epidermis and depositing them in the "G7F-sebo2D" culture medium as defined hereinbelow,
7) incubating the sampled sebaceous glands in trypsin, preferably for 5 to 10 min, then inhibiting the trypsin, for example by adding "G7F-sebo2D" culture medium as defined hereinbelow,
8) centrifuging the trypsinized sebaceous glands, preferably at 190 g, resuspending them and seeding them on feeder cells seeded beforehand, for example on irradiated fibroblasts such as 3T3i fibroblasts, in the "G7F-sebo2D" culture medium as defined hereinbelow further comprising a ROCK inhibitor as defined hereinbelow, preferably the Y-27632 compound, typically at 10 μΜ. Method of amplification
As indicated hereinabove, the inventors have developed a method that makes it possible to amplify non-immortalized primary sebocytes, in such a way as to retain their potential for differentiation during the preparation of the in vitro model of reconstructed sebocyte epithelium.
This method involves the use of a ROCK inhibitor in the presence of feeder cells in a culture medium comprising 7 factors enabling the growth of the sebocytes. This use makes it possible to retain the proliferative power of the primary sebocytes by reversibly blocking their differentiation, and thereby, to form substantial stocks of primary sebocytes.
The present invention thus relates to a method, preferably in vitro, for amplifying primary sebocytes, as defined in the "Sebocytes" section hereinabove, comprising a step of culture, in the presence of feeder cells, of primary sebocytes, as defined in the "Sebocytes" section hereinabove, preferably non-immortalized primary sebocytes, in particular non-immortalized primary human sebocytes, in a "G7F-sebo2D" culture medium comprising:
(i) adenine hydrochloride,
(ii) epidermal growth factor (EGF), (iii) hydrocortisone,
(iv) insulin,
(v) isoproterenol,
(vi) transferrin, and
(vii) triiodothyronine,
said culture medium further comprising a ROCK inhibitor.
The term "amplification" here means the proliferation or multiplication of cells.
Preferably, the cultivated primary sebocytes are non-immortalized primary human sebocytes, preferably coming from sebaceous glands coming for example from surgical waste, such as lifting waste. In a particular embodiment, the cultivated primary sebocytes come from the method of extraction defined in the "Sebocytes" section hereinabove.
Thus, in a particular embodiment, the method of amplification according to the invention comprises, before the step of culture, a step of extracting sebocytes, in particular from surgical waste, implementing the method of extraction defined in the "Sebocytes" section hereinabove.
The term "feeder cell" here means cells used in culture with other types of cells and which assist in the growth thereof. Feeder cells have their growth stopped, for example by irradiation, but are viable and form a substrate whereon the other cells can grow. In a particular embodiment, the feeder cells are fibroblasts, such as fibroblasts from fibroblast lines, for example 3T3 fibroblasts, and most preferably irradiated 3T3 fibroblasts, also called 3T3i.
The "G7F-sebo2D" culture medium used in the method of amplification according to the invention is a nutrient medium comprising a base medium and the 7 following factors that allow for the growth of the sebocytes:
(i) adenine hydrochloride,
(ii) epidermal growth factor (EGF),
(iii) hydrocortisone,
(iv) insulin,
(v) isoproterenol,
(vi) transferrin, and
(vii) triiodothyronine,
The base medium can in particular be a DMEM medium, DMEM/F12, MEM, RPMI medium, William's medium, KGM medium, dermalife-K medium, keratinocyte-SFM medium, or Glasgow medium. Preferably, the base medium is DMEM/F12 medium. Preferably, the base medium further contains L-glutamine, preferably at a concentration of 0.5 to 20 mM, more preferably at a concentration of 2 to 10 mM, still preferably at a concentration of 4 to 5 mM. Preferably, the base medium further comprises fetal calf serum, preferably at a concentration from 5 to 20%, and more preferably at a concentration of 10%.
The "G7F-sebo2D" culture medium may further comprise antibiotics.
The "G7F-sebo2D" culture medium comprises the following 7 factors that allow for sebocyte growth:
(i) adenine hydrochloride, preferably at a concentration from 1 x10~4 M to 2x10"4 M, in particular at a concentration from 1 .4x10"4 to 1 .9x10"4 M, more particularly from 1 .5x10"4 to 1 .8x10"4 M or from 1 .6x10"4 to 1 .7x10"4 M,
(ii) epidermal growth factor (EGF), for example recombinant human EGF, preferably at a concentration from 5 to 25 ng/ml, in particular at a concentration from 7 to 20 ng/ml, more particularly from 8 to 15 ng/ml, and more particularly from 9 to 12 ng/ml or from 10 to 1 1 ng/ml,
(iii) hydrocortisone, for example hydrocortisone 21 -hemisuccinate sodium, preferably at a concentration from 0.1 to 1 μg/ml, in particular at a concentration from 0.2 to 0.9 μg/ml, more particularly from 0.3 to 0.8 μg/ml, from 0.4 to 0.7 μg/ml or from 0.5 to 0.6 μg/m\,
(iv) insulin, for example recombinant human insulin, preferably at a concentration from 1 to 10 μg/ml, in particular at a concentration from 2 to 9 μg/ml, more particularly from 3 to 8 μg/ml, from 4 to 7 μg/ml or from 5 to 6 μg/ml,
(v) isoproterenol (also called isoprenaline), for example (-)-isoproterenol hydrochloride, preferably at a concentration from 5x10"7 to 5x10"6 M, in particular at a concentration from 6x10"7 to 4x10"6 M, more particularly from 7x10"7 to 3x10"6 M, from 8x10"7 to 2x10"6 M or from 9x10"7 to 1 x10"6 M,
(vi) transferrin (also called siderophilin), preferably human transferrin, for example human apo-transferrin, preferably at a concentration from 1 to 10 μg/ml, in particular at a concentration from 2 to 9 μg/ml, more particularly from 3 to 8 μg/ml, from 4 to 7 μg/ml or from 5 to 6 μg/ml, and
(vii) triiodothyronine (also called 3,3',5-triiodo-L-thyronine or T3), for example 3, 3', 5- triiodo-L-thyronine sodium, preferably at a concentration from 1 x10~9 to 5x10"9 M, in particular at a concentration from 1 .5x10"9 to 4x10"9 M, more particularly from 1 .75x10"9 to 3x10"9 M or from 2x10"9 to 2.5x10"9 M.
In a particular embodiment, the "G7F-sebo2D" culture medium comprises:
(i) from 1 x10~4 to 2x10"4 M of adenine hydrochloride,
(ii) from 5 to 25 ng/ml of EGF, (iii) from 0.1 to 1 μg/ml of hydrocortisone,
(iv) from 1 to 10 μg/ml of insulin,
(v) from 5x10"7 to 5x10"6 M of isoproterenol,
(vi) from 1 to 10 μg/ml of transferrin, preferably human transferrin, and
(vii) from 1 x10"9 to 5x10"9 M of triiodothyronine.
In a particular embodiment, the "G7F-sebo2D" culture medium comprises:
(i) from 1 .5x10"4 to 1 .8x10"4 M of adenine hydrochloride,
(ii) from 9 to 12 ng/ml of EGF,
(iii) from 0.4 to 0.7 μg/ml of hydrocortisone,
(iv) from 4 to 7 μg/ml of insulin,
(v) from 8x10"7 to 2x10"6 M of isoproterenol,
(vi) from 4 to 7 μg/ml of transferrin, preferably human transferrin, and
(vii) from 1 .75x10"9 to 3x10"9 M of triiodothyronine.
In the method of amplification according to the invention, the "G7F-sebo2D" culture medium further comprises a ROCK inhibitor.
The term "ROCK inhibitor" here means a protein, a nucleic acid, a small molecule, an antibody or another agent that prevents the expression of ROCK or decreases the activity of ROCK such as its kinase activity. ROCK inhibitors are well known to those skilled in the art and include the compound Y-27632 and the compounds H-1 152, Y- 30141 , Wf-536, HA-1077, hydroxyl-HA-1077, GSK269962A and SB-772077-B.
Preferably, the ROCK inhibitor is the compound Y-27632.
The ROCK inhibitor, in particular the compound Y-27632, is preferably added to the "G7F-sebo2D" culture medium at a concentration from 5 to 15 μΜ, preferably from 6 to 14 μΜ, more preferably from 7 to 13 μΜ, from 8 to 12 μΜ, from 9 to 1 1 μΜ, and most preferably at a concentration of 10 μΜ.
The culture medium is preferably changed regularly during the culture of the sebocytes, for example every 1 , 2 or 3 days.
The primary sebocytes thereby amplified can be trypsinized and re-seeded as soon as a high level of confluence is obtained, for example a level of confluence of 70%.
Method for preparing a model of reconstructed sebocyte epithelium. As indicated hereinabove, the inventors have furthermore developed a method for preparing a model of reconstructed sebocyte epithelium that implements non-immortalized primary sebocytes that makes it possible to obtain a three-dimensional model that is physiologically more pertinent with respect to the models described until now. Another object of the invention thus relates to a method, preferably in vitro, for preparing a model of reconstructed sebocyte epithelium that comprises the steps consisting in:
a) seeding, on a biomaterial for reconstructed epidermis (BPER) optionally covered with extracellular matrix protein, non-immortalized primary sebocytes in suspension in a "G7F-ERS" culture medium comprising:
(i) adenine hydrochloride,
(ii) epidermal growth factor (EGF),
(iii) hydrocortisone,
(iv) insulin,
(v) isoproterenol,
(vi) transferrin, and
(vii) triiodothyronine;
b) cultivating the sebocytes seeded in step a) in immersion on said BPER in G7F- ERS medium for 1 to 4 days;
c) cultivating the sebocytes obtained in step b) at the air - liquid interface on said BPER above a "G3F-ERS" culture medium comprising:
(I) epidermal growth factor (EGF),
(II) hydrocortisone, and
(III) insulin,
said G3F-ERS medium further comprising linoleic acid and a PPAR agonist, for a period that is suitable for allowing the differentiation of the sebocytes and lipid synthesis,
said model of reconstructed sebocyte epithelium being obtained at the end of step c).
The term "biomaterial for reconstructed epidermis" or "BPER" here means a dermal equivalent, used as a support and integrating ingredients that are naturally present in the dermis. Preferably, the BPER is a matrix of collagen, in particular of type I and/or IV collagens.
Preferably, the BPER is covered with extracellular matrix protein.
Extracellular matrix proteins are well known to those skilled in the art and include collagen, such as type IV or type VII collagen, fibronectin and laminin. Preferably, the BPER is covered with fibronectin, in particular human fibronectin.
The non-immortalized primary sebocytes seeded in step a) are as defined in the "Sebocytes" section hereinabove. Preferably, these are non-immortalized primary human sebocytes, preferably pre-amplified by the method of amplification as defined in the "Method of amplification" section hereinabove but in the absence of ROCK inhibitor.
Thus, in a particular embodiment, the method of preparation according to the invention comprises, before the step a) of seeding, a step pre-a) of pre-amplifying the non-immortalized primary sebocytes, preferably implementing the method of amplification as defined in the "Method of amplification" section hereinabove but in the absence of a ROCK inhibitor, in other words in the "G7F-Sebo2D" culture medium, as defined in the "Method of amplification" section, that does not contain any ROCK inhibitor.
The "G7F-ERS" culture medium used in the method of preparation according to the invention is a nutrient medium comprising a base medium and the 7 following factors that allow for the growth of the sebocytes:
(i) adenine hydrochloride,
(ii) epidermal growth factor (EGF),
(iii) hydrocortisone,
(iv) insulin,
(v) isoproterenol,
(vi) transferrin, and
(vii) triiodothyronine.
The base medium can in particular be a DMEM medium, DMEM/F12, MEM, RPMI medium, William's medium, KGM medium, dermalife-K medium, keratinocyte-SFM medium or Glasgow medium. Preferably, the base medium is DMEM/F12 medium. Preferably, the base medium further contains L-glutamine, preferably at a concentration of 0.5 to 20 mM, more preferably at a concentration of 2 to 10 mM, more preferably at a concentration of 4 to 5 mM. Preferably, the base medium further comprises fetal calf serum, preferably at a concentration from 5 to 20%, and more preferably at a concentration of 10%.
The "G7F-ERS" culture medium may further comprise antibiotics, sodium pyruvate preferably at a concentration of 0.1 to 10 mM, non-essential amino acids such as those contained in the MEM Non-Essential Amino Acids Solution (100X) product commercialized by Gibco under the reference 1 1 140, in particular diluted 100 times.
The "G7F-ERS" culture medium comprises the following 7 factors that allow for sebocyte growth:
(i) adenine hydrochloride, preferably at a concentration from 1 x10~4 M to 2x10"4 M, in particular at a concentration from 1 .4x10"4 to 1 .9x10"4 M, more preferably from 1 .5x10"4 to 1 .8x10"4 M or from 1 .6x10"4 to 1 .7x10"4 M, (ii) epidermal growth factor (EGF), for example recombinant human EGF, preferably at a concentration from 30 to 75 ng/ml, in particular at a concentration from 35 to 70 ng/ml, more preferably from 40 to 65 ng/ml, 45 to 60 ng/ml or from 50 to 55 ng/ml,
(iii) hydrocortisone, for example hydrocortisone 21 -hemisuccinate sodium, preferably at a concentration from 0.1 to 1 μg/ml, in particular at a concentration from 0.2 to 0.9 μg/ml, more preferably from 0.3 to 0.8 μg/ml, from 0.4 to 0.7 μg/ml or from 0.5 to 0.6 Mg ml,
(iv) insulin, for example recombinant human insulin, preferably at a concentration from 1 to 10 μg/ml, in particular at a concentration from 2 to 9 μg/ml, more preferably from 3 to 8 μg/ml, from 4 to 7 μg/ml or from 5 to 6 μg/ml,
(v) isoproterenol (also called isoprenaline), for example (-)-isoproterenol hydrochloride, preferably at a concentration from 5x10"7 to 5x10"6 M, in particular at a concentration from 6x10"7 to 4x10"6 M, more preferably from 7x10"7 to 3x10"6 M, from 8x10"7 to 2x10"6 M or from 9x10"7 to 1 x10"6 M,
(vi) transferrin (also called siderophilin), preferably human transferrin, for example human apo-transferrin, preferably at a concentration from 1 to 10 μg/ml, in particular at a concentration from 2 to 9 μg/ml, more preferably from 3 to 8 μg/ml, from 4 to 7 μg/ml or from 5 to 6 μg/ml, and
(vii) triiodothyronine (also called 3,3',5-triiodo-L-thyronine or T3), for example 3, 3', 5- triiodo-L-thyronine sodium, preferably at a concentration from 1 x10~9 to 5x10"9 M, in particular at a concentration from 1 .5x10"9 to 4x10"9 M, more preferably from 1 .75x10"9 to 3x10"9 M or from 2x10"9 to 2.5x10"9 M.
In a particular embodiment, the "G7F-ERS" culture medium comprises:
(i) from 1 x10~4 to 2x10"4 M of adenine hydrochloride,
(ii) from 30 to 75 ng/ml of EGF,
(iii) from 0.1 to 1 μg/ml of hydrocortisone,
(iv) from 1 to 10 μg/ml of insulin,
(v) from 5x10"7 to 5x10"6 M of isoproterenol,
(vi) from 1 to 10 μg/ml of transferrin, preferably human transferrin, and
(vii) from 1 x10~9 to 5x10"9 M of triiodothyronine.
In a particular embodiment, the "G7F-ERS" culture medium comprises:
(i) from 1 .5x10"4 to 1 .8x10"4 M of adenine hydrochloride,
(ii) from 45 to 65 ng/ml of EGF,
(iii) from 0.4 to 0.7 μg/ml of hydrocortisone,
(iv) from 4 to 7 μg/ml of insulin, (v) from 8x10"7 to 2x10"6 M of isoproterenol,
(vi) from 4 to 7 μg/ml of transferrin, preferably human transferrin, and
(vii) from 1 .75x10"9 to 3x10"9 M of triiodothyronine.
After the step of seeding, the sebocytes are advantageously cultivated in immersion in the G7F-ERS medium, as defined hereinabove, for 1 to 4 days, preferably for 3 days.
During this step b) of culture, the G7F-ERS culture medium can be replaced regularly, for example every day or every 2 days.
This step of culture allows for the proliferation of the sebocytes.
This step b) of culture in immersion is followed by a step c) of culture of sebocytes at the air - liquid interface on the BPER above a "G3F-ERS" culture medium comprising:
(I) epidermal growth factor (EGF),
(II) hydrocortisone, and
(III) insulin,
and further comprising linoleic acid and a PPAR agonist.
The "G3F-ERS" culture medium used in the method of preparation according to the invention is a nutrient medium comprising a base medium and the 3 following factors that allow for the growth and/or differentiation of the sebocytes:
(I) epidermal growth factor (EGF),
(II) hydrocortisone, and
(III) insulin.
The base medium can in particular be DMEM medium, DMEM/F12, MEM, RPMI medium, William's medium, KGM medium, dermalife-K medium, keratinocyte-SFM medium or Glasgow medium. Preferably, the base medium is DMEM/F12 medium. Preferably, the base medium further contains L-glutamine, preferably at a concentration of 0.5 to 20 mM, more preferably at a concentration of 2 to 10 mM, still preferably at a concentration of 4 to 5 mM. Preferably, the base medium further comprises fetal calf serum, preferably at a concentration from 5 to 20%, more preferably at a concentration of 10%.
The "G3F-ERS" culture medium comprises the following 3 factors that allow for sebocyte growth and/or differentiation:
(I) epidermal growth factor (EGF), for example recombinant human EGF, preferably at a concentration from 30 to 75 ng/ml, in particular at a concentration from 35 to 70 ng/ml, from 40 to 65 ng/ml, 45 to 60 ng/ml or from 50 to 55 ng/ml, (II) hydrocortisone, for example hydrocortisone 21 -hemisuccinate sodium, preferably at a concentration from 0.1 to 1 μg/ml, in particular at a concentration from 0.2 to 0.9 μg/ml, from 0.3 to 0.8 μg/ml, from 0.4 to 0.7 μg/ml or from 0.5 to 0.6 μg/ml, and
(III) insulin, for example recombinant human insulin, preferably at a concentration from 1 to 10 μg/ml, in particular at a concentration from 2 to 9 μg/ml, from 3 to 8 μg/ml, from 4 to 7 μg/ml or from 5 to 6 μ9ΛηΙ.
The "G3F-ERS" medium thus has the particularity of comprising only 3 factors that allow for sebocyte growth and/or differentiation. Preferably, the "G3F-ERS" medium is devoid of adenine hydrochloride, isoproterenol, human transferrin and/or triiodothyronine.
In a particular embodiment, the "G3F-ERS" culture medium comprises:
(I) from 30 to 75 ng/ml of EGF,
(II) from 0.1 to 1 μg/ml of hydrocortisone, and
(III) from 1 to 10 μg/ml of insulin.
In a particular embodiment, the "G3F-ERS" culture medium comprises:
(I) from 45 to 65 ng/ml of EGF,
(II) from 0.4 to 0.7 μg/ml of hydrocortisone, and
(III) from 4 to 7 μg/ml of insulin.
The "G3F-ERS" medium can furthermore comprise vitamin C, preferably at a concentration from 0.05 to 0.5 mg/ml, in particular at a concentration from 0.06 to 0.4 mg/ml, from 0.07 to 0.3 mg/ml, from 0.08 to 0.2 mg/ml or from 0.09 to 0.1 mg/ml.
The "G3F-ERS" medium can further comprise antibiotics, sodium pyruvate preferably at a concentration of 0.1 to 10 mM, non-essential amino acids such as those contained in the MEM Non-Essential Amino Acids Solution (100X) product commercialized by Gibco under the reference 1 1 140, in particular diluted 100 times.
The "G3F-ERS" medium as defined hereinabove further comprises linoleic acid and a PPAR agonist.
These additional compounds act in the method of preparation according to the invention as inducers of differentiation and of lipid synthesis.
In a particular embodiment, the "G3F-ERS" medium comprises several PPAR agonists, in particular at least two PPAR agonists, preferably at least three PPAR agonists.
The term "PPAR (peroxisome proliferator-activated receptor) agonist" or "PPAR inducer" here means a compound that activates the signaling pathway mediated by PPAR.
The term "PPAR" or "peroxisome proliferator-activated receptor" here means a protein of the superfamily of nuclear receptors that naturally binds lipids and that acts as a transcription factor of genes involved in particular in metabolism and adipogenesis. Three types of PPAR have been identified: alpha, gamma and delta (beta). Like all nuclear receptors, PPAR is structured in four separate regions. An N-terminal domain has a transactivating function independent of the ligand (AF-1 ). The DNA binding domain or DBD is constituted of two zinc fingers characteristic of the superfamily of nuclear receptors. PPAR has a hinge region preceding the ligand binding domain or LBD that has a transactivating function dependent of the ligand (AF-2).
The PPAR agonist used in the context of the invention can be a pan-PPAR agonist (i.e. an inducer of the three types of PPAR, alpha, gamma and beta/delta), a selective PPAR-alpha agonist and/or a selective PPAR-delta agonist and/or a selective PPAR- gamma agonist.
Examples of PPAR agonists are well known to those skilled in the art and include, as a pan-PPAR agonist, aleglitazar, muraglitazar, saroglitazar and tesaglitazar, as a selective PPAR-delta agonist, the compound GW501516 ({4-[({4-methyl-2-[4- (trifluoromethyl)phenyl]-1 ,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid), and the compound GW0742 ([4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5- thiazolyl]methyl]thio]-2-methylphenoxy]-acetic acid) referenced as CAS [317318-84-6], as a PPAR-alpha agonist, derivatives of fibric acid such as aluminum cofibrate, beclobrate, bezafibrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, clofibric acid, clofibride, dulofibrate, eniclobrate, ethofibrate, etofylline clofibrate, fenofibrate, fenofibric acid, gemfibrozil, nicofibrate, pirifibrate, ronifibrate, simfibrate and theofibrate.
Preferably, the PPAR agonist used in the context of the invention is the compound GW0742.
Advantageously, the "G3F-ERS" medium contains only one PPAR agonist, preferably the PPAR agonist is the compound GW0742.
In a particular embodiment, the "G3F-ERS" medium comprises from 1 x10~7 to 2.5x10"5 M of linoleic acid, preferably from 5x10"7 to 2x10"5 M, from 1 x10~6 to 1 .5x10"5 M, from 5x10"6 to 1 x10"5 M, or from 9x10"6 to 1 x10"5 M.
In another particular embodiment, the "G3F-ERS" medium comprises from 1 x10~6 to 5x10"6 M of a PPAR agonist, in particular of compound GW0742, preferably from 1 .5x10"6 to 4x10"6 M, from 2x10"6 to 3.5x10"6 M or from 2.5x10"6 to 3x10"6 M.
In a particular embodiment, the "G3F-ERS" medium comprises from 5x10"6 to 2.5x10"5 M of linoleic acid and from 1 x10~6 to 5x10"6 M of a PPAR agonist, said PPAR agonist being preferably the compound GW0742. In a particular embodiment, the "G3F-ERS" medium comprises from 8x10"6 to 2x10"5 M of linoleic acid and from 2x10"6 to 5x10"6 M of a PPAR agonist, said PPAR agonist being preferably the compound GW0742.
It is during this phase c) of culture at the air-liquid interface that the sebocytes differentiate and produce a mixture of neutral lipids (such as glycerides, cholesterol, esters of cholesterol and free fatty acids).
Thus, the step c) of culture at the air-liquid interface is implemented during a suitable duration for allowing the differentiation of sebocytes and lipid synthesis.
Preferably, the step c) of culture at the air-liquid interface is implemented for 5 to 25 days, preferably for 7 to 20 days, for 8 to 17 days or for 10 to 15 days.
In particular, the step c) of culture at the air-liquid interface can be continued once the sebocytes are differentiated, for example in order to use the obtained model in screening tests.
During the step c) of culture at the air-liquid interface, the G3F-ERS culture medium can be replaced regularly, partially or entirely, for example every day, every 2 days or every 3 days.
The model of reconstructed sebocyte epithelium is obtained at the end of step c). This model is different from the models of sebocyte epithelium of the state of the art by the fact that the sebocytes that form it are not immortalized and that its histology is very close to that of the in vivo sebaceous gland. In particular, almost all of the large families of non-polar lipids (glycerides, cholesterol, fatty acids, esters of cholesterol) present in the sebum are present in the model of reconstructed sebocyte epithelium obtained by the preparation method according to the invention
The present invention therefore also concerns a model of reconstructed sebocyte epithelium likely to be obtained by the preparation method according to the invention.
Uses
The inventors have shown that the lipid synthesis of the model of reconstructed sebocyte epithelium according to the invention could be modulated using compounds known for modulating this activity in vivo such as 13-cis-retinoic acid.
The model of reconstructed sebocyte epithelium according to the invention can therefore be used to identify compounds that modulate the lipid synthesis of sebocytes.
The present invention thus relates to a method, preferably in vitro, for screening compounds that modulate the lipid synthesis of sebocytes, comprising putting into contact a candidate compound with the model of reconstructed sebocyte epithelium according to the invention. The present invention also has for object a method, preferably in vitro, for screening compounds for treating oily and/or glistening skin, comprising putting into contact a candidate compound with the model of reconstructed sebocyte epithelium according to the invention.
The screening methods according to the invention can further comprise a step of analyzing lipids synthesized by the sebocytes of the model of reconstructed sebocyte epithelium in the presence of the candidate compound, for example by labeling neutral lipids, for example with BODIPY, Lipidtox or oil-red-o. The present invention shall be illustrated in more detail by the figures and example hereinbelow.
Brief description of the figures
Figure 1 : Scheme of extraction of primary human sebocytes obtained from a biopsy.
Figure 2: Observations under the microscope of sebocytes extracted from sebaceous glands after 6 days of culture on plastic. Part A: culture in G7F-sebo2D medium - Part B: culture in G7F-sebo2D medium in the presence of a ROCK inhibitor (Y27632).
Figure 3: A: Example of a histological section of an in vivo sebaceous gland adapted from Woldow et al. (2009) Dermatology Online Journal 15:14. B: Scheme representing an in vivo sebaceous gland adapted from Niemann et al. (2012) Seminars in Cell & Developmental Biology 23:928-936.
Figure 4: Left part: Examples of histological sections of the model of reconstructed sebocyte epithelium according to the invention at D13 colored with HES.
Right part: for comparison, example of a histological section of the EPISKIN epidermis model colored with HES.
Figure 5: Compilation of 3 studies of modulation of the synthesis of neutral lipids on the model of reconstructed sebocyte epithelium according to the invention carried out by BODIPY labeling and analyzing IMAGEJ images. 4 molecules evaluated: isotretinoin (= 13-cis-retinoic acid) at 1 μΜ (Iso), compound A at 50 μΜ (A), compound B at 20 μg/ml (B) and compound C at 10 μg/ml (C). Two controls were carried out: an non-treated control (NC) and a control treated with the solvent DMSO (DMSO). The bar graphs show the surface labeled with BODIPY standardized with respect to untreated controls, the percentage indicated above the bar graphs corresponding to the percentage of surfaces labeled with respect to the DMSO control.
** p < 0.05 vs. DMSO, *** p < 0.005 vs. DMSO, Student's T test
Examples
Example 1 : Extraction of primary human sebocytes obtained from a biopsy
This example describes the extraction of primary human sebocytes carried out by using the extraction protocol according to the invention.
Pieces of lifting comprising hairs were used.
The medium in which the pieces of lifting were stored and the blood were eliminated.
The pieces of lifting were selected and placed in a Petri dish containing PBS. The surface of the skin was shaved using a scalpel in order to remove the hair.
The pieces were then cut into pieces of about 0.5 cm2 and placed in a bath of antibiotics (medium with 10% antibiotics) for 20 min.
3T3i irradiated fibroblasts were defrosted and seeded in the "G7F-sebo2D" medium comprising 10 μΜ of Y-27632.
The pieces of skin were covered with an aqueous solution of Dispase II at 2.4 U/ml, and incubated at 4°C overnight or 2h at 37°C.
The dispase was then removed, the pieces rinsed in PBS, and the epidermis was separated from the dermis by using microdissection tweezers. The dermis was eliminated. The sebaceous gland of each hair follicle found under the epidermis was removed and deposited into a well comprising "G7F-sebo2D" medium.
Composition of the G7F-sebo2D medium supplemented with antibiotics for a final volume of 500 ml:
Product Volume or final Reference concentration
DMEM Glutamax 333 ml Gibco n° 31966
F12 Glutamax 1 1 1 ml Gibco n° 31765
FetalClone II Serum 10% Hyclone n°SH30066.03
Antibiotics-antimycotics 1 % Gibco n° 15240-062
Adenine hydrochloride 1 .8x10"4 M Sigma n° A-9795
EGF 10 ng/ml Chemicon internal ref. GF144 Hydrocortisone 0.4 μg/ml Sigma n° H-4881
Insulin 5 μ9/ηιΙ Sigma n° I-9278
Isoproterenol 10-6 M Sigma n° I-6504
Human transferrin 5 μο/ηιΙ Sigma n° T-2252
Triiodothyronine 2x10"9 M Sigma n° T-2752
The medium comprising the glands was then recovered and centrifuged 8 min at 190 g. The supernatant was eliminated and the glands were resuspended in trypsin. After 5 to 10 min of incubation, the tubes were vortexed in order to dissociate the glands. The trypsin was then inhibited by adding "G7F-sebo2D" medium supplemented with antibiotics.
The whole was then centrifuged for 8 min at 190 g and the pellet was resuspended.
The cells were counted with trypan blue then seeded on the fibroblasts in culture in "G7F-sebo2D" medium supplemented with antibiotics and comprising 10 μΜ of Y-27632.
This method of extraction is shown in Figure 1.
Example 2: Method for amplifying non-immortalized human sebocytes
This example describes the amplification of primary human sebocytes carried out by using the method of amplification according to the invention.
Composition of the G7F-sebo2D medium supplemented with antibiotics for a final volume of 500 ml:
Figure imgf000019_0001
10 μΜ of Y-27632 were added to the "G7F-sebo2D" medium supplemented with antibiotics. The day before, or 2 hours before the seeding of the sebocytes, 3T3i fibroblasts were seeded in G7F-sebo2D medium supplemented with antibiotics + Y27632, at a rate of 40,000 cells / cm2.
The non-immortalized primary human sebocytes were put into suspension in G7F- sebo2D medium + Y27632, and seeded on the fibroblasts at a rate of 2,400 cells / cm2.
The culture medium was changed every 48h.
After 5 days of culture, the cells arrived at confluence and about 5 million sebocytes could be recovered by trypsinization.
Figure 2 shows microscopic observations of sebocytes after 6 days of culture on plastic in G7F-sebo2D medium supplemented with antibiotics with and without Y27632.
Example 3: Method for preparing a model of reconstructed sebocyte epithelium.
This example describes the preparation of a model of reconstructed sebocyte epithelium from non-immortalized primary human sebocytes using the method of preparation according to the invention.
Preparation of BPERs
The BPERs comprising type I and type IV collagen were rinsed twice in PBS and once in DMEM/F12 Glutamax 3:1 base medium + antibiotics.
The BPERs were then coated with fibronectin the day before inoculation of sebocytes.
Amplification of sebocytes
The 3T3i fibroblasts and the sebocytes were either co-seeded, or seeded sequentially, the sebocytes then being seeded at least 2h after the fibroblasts.
The "G7F-sebo2D" culture medium supplemented with antibiotics was used:
Composition of the "G7F-sebo2D" medium supplemented with antibiotics for a final volume of 500 ml:
Product Volume or final Reference concentration
DMEM Glutamax 333 ml Gibco no. 31966
F12 Glutamax 1 1 1 ml Gibco no. 31765
FetalClone II Serum 10% Hyclone no. SH30066.03
Antibiotics-antimycotics 1 % Gibco no. 15240-062
Adenine hydrochloride 1 .8x10"4 M Sigma no. A-9795 EGF 10 ng/ml Chemicon internal ref. GF144
Hydrocortisone 0.4 μg/ml Sigma no. H-4881
Insulin 5 μ9/ηιΙ Sigma no. I-9278
Isoproterenol 10-6 M Sigma no. I-6504
Human transferrin 5 μο/ηιΙ Sigma no. T-2252
Triiodothyronine 2x10"9 M Sigma no. T-2752
The flask comprising the cells was incubated at 37°C with 5% of C02 for 6 days, changing the medium every two days.
Seeding of the sebocvtes on BPER
"G7F-ERS" medium supplemented with L-glutamine, sodium pyruvate, nonessential amino acids, fetal bovine serum and antibiotics, was deposited under BPER inserts.
Composition of the supplemented "G7F-ERS" medium for a final volume of 500 ml:
Figure imgf000021_0001
The amplified sebocytes were trypsinized, centrifuged at 190 g and resuspended in supplemented "G7F-ERS" medium in such a way as to obtain a suspension at 0.8.106 cells/ml.
500 μΙ of cell suspension were deposited on each BPER (DO) and incubated at 37°C, 5% C02.
Culture in immersion from DO to D3:
On D1 , the culture medium was renewed with "G7F-ERS" medium above and under each insert. Culture in emersion from D3 to D13:
On D3, D6, D8 and D10, the culture medium above and under the inserts was aspirated. "G3F-ERS" medium supplemented with L-glutamine, sodium pyruvate, nonessential amino acids, fetal bovine serum, antibiotics, vitamin C, linoleic acid and GW0742, was deposited under each insert.
Composition of the G3F-ERS medium for a final volume of 500 ml:
Figure imgf000022_0001
They were then incubated at 37°C, 5% C02.
It is during this phase of culture in particular that the sebocytes differentiate and produce a mixture of neutral lipids (glycerides, cholesterol, esters of cholesterol, free fatty acids).
Figure 4 shows histological sections of the model obtained at the end of this protocol, compared to an Episkin epidermis model (referenced EPISKIN/L/13 by EPISKIN S.A.) and to an in vivo sebaceous gland (Figure 3).
Example 4: Study of the modulation of the synthesis of the neutral lipids by different molecules in a model of reconstructed sebocyte epithelium according to the invention
This example shows that the lipid synthesis of the model of reconstructed sebocyte epithelium according to the invention can be modulated by using compounds known to modulate this activity in vivo such as 13-cis-retinoic acid and that the model of reconstructed sebocyte epithelium according to the invention can therefore be used to identify compounds that modulate the lipid synthesis of sebocytes. Materials and methods
Labeling of lipids with BODIPY:
BODIPY® (493/503) is a fluorochrome that has a particular affinity for neutral lipids.
Products:
Figure imgf000023_0001
This labeling is carried out on sections of 10 μηι thick obtained from cryomicrotom sections of samples frozen at OCT (Optimal Cutting Temperature).
The following protocol was implemented:
- Take the blades for labeling out of the freezer, let them dry flat for about 30 min.
- Fixation: 4% formaldehyde bath 20 min at room temperature
- Allow to dry under the fume cupboard until there is no more formaldehyde
- Surround the sections with Dako pen (allow to dry well)
- PBS rinsing 5 min at +4°C
- Incubation in PBS + goat serum 10% + BSA 1 %: 100μΙ /section, 20 min at room temperature in a wet chamber, in the dark
- Preparation PBS + BSA 1 %: 10g BSA + 1 liter PBS histo
- Preparation PBS + BSA 1 %+- goat serum 10%: 1 ,ΟΟΟμΙ -Goat serum + 9,000μΙ PBS+BSA 1 %
- PBS rinsing 5 min at +4°C
- Bodipy Incubation 1 h at room temperature in a wet chamber, in the dark, 100μΙ /section
- Preparation of PBS +- goat serum 10%: 1 .5ml - Goat serum + 13.5ml PBS.
- Bodipy preparation at 25μg/ml (dilution to 1/40 of aliquots prepared beforehand at 1 mg/ml DMSO), 250μΙ Bodipy 1 mg/ml + 9750 μΙ PBS + -Goat serum.
- PBS rinsing 5min at +4°C
- Incubation with Hoechst 1/1000 5 min at room temperature in a wet chamber, in the dark, 100μΙ /section - Hoechst Preparation: 15μΙ Hoechst + 15 ml PBS
- 2 PBS rinsings 5 min at +4°C
- Mounting the coverglasses with Fluoromount G. Acquisition and analysis of the labeling:
The acquisition of the fluorescence images is carried out under standardized conditions (exposure time, white-black settings...) and with a magnification that makes it possible to visualize the epithelium over its entire thickness.
The images were acquired in fluorescence with a Zeiss Axioplan 2 imaging microscope combined with a Zeiss AxioCam MRm camera, and with the Zeiss ZEN lite image acquisition software. Images are recorded in a format that is compatible with the image analysis software and with the scale of the sizes.
Analysis of images is carried out with IMAGEJ: the labelling is thus selected, and the labeled surface is measured for each sample.
In order to have a more robust evaluation, this analysis is conducted over several fields per histological section, and over several histological sections per biological sample. For each sample the measurements are averaged, and for each test condition the average of the replicates per treatment condition is taken.
If an agent has been tested over several studies, the results can be standardized with respect to the untreated control in order to be able to express a significance over all of the tests conducted.
Results
Figure 4 shows the results obtained by labeling with BODIPY and image analysis with IMAGEJ. For each condition the surface results were obtained by compiling 3 different studies after standardizing values with respect to the untreated controls. All of the compounds tested being solubilized in DMSO, a solvent control was integrated into each study. Isotretinoin was used as a pharmaceutical reference or positive control for the functionality of the model, and made it possible to validate the studies. 3 cosmetic compounds were evaluated in parallel (compounds A, B and C).
Compounds A and B made it possible to decrease the synthesis of neutral lipids, contrary to compound C which did not show any activity in this test.

Claims

1. In vitro method for amplifying primary sebocytes, said method comprising a step of culture, in the presence of feeder cells, of primary sebocytes, preferably human non- immortalized primary sebocytes, in a "G7F-sebo2D" culture medium comprising:
(i) adenine hydrochloride,
(ii) epidermal growth factor (EGF),
(iii) hydrocortisone,
(iv) insulin,
(v) isoproterenol,
(vi) transferrin, and
(vii) triiodothyronine,
said culture medium further comprising a ROCK inhibitor.
2. Method for amplifying according to claim 1 , wherein the ROCK inhibitor is the compound Y-27632, the compound Y-27632 being preferably present in the culture medium at a concentration of 10 μΜ.
3. Method of amplifying according to claim 1 or 2, wherein the "G7F-sebo2D" culture medium comprises:
(i) from 1 x10~4 to 2x10"4 M of adenine hydrochloride,
(ii) from 5 to 25 ng/ml of EGF,
(iii) from 0.1 to 1 μg/ml of hydrocortisone,
(iv) from 1 to 10 μg/ml of insulin,
(v) from 5x10"7 to 5x10"6 M of isoproterenol,
(vi) from 1 to 10 μg/ml of transferrin, preferably human transferrin, and
(vii) from 1 x10~9 to 5x10"9 M of triiodothyronine.
4. Method for amplifying according to any one of claims 1 to 3, wherein the primary sebocytes are non-immortalized primary human sebocytes coming from sebaceous glands coming from surgical waste.
5. In vitro method for preparing a model of reconstructed sebocyte epithelium, said method comprising the steps consisting in: a) seeding, on a biomaterial for reconstructed epidermis (BPER) optionally covered with extracellular matrix protein, non-immortalized primary sebocytes in suspension in a "G7F-ERS" culture medium comprising:
(i) adenine hydrochloride,
(ii) epidermal growth factor (EGF),
(iii) hydrocortisone,
(iv) insulin,
(v) isoproterenol,
(vi) transferrin, and
(vii) triiodothyronine;
b) cultivating the sebocytes seeded in step a) in immersion on said BPER in "G7F- ERS" medium for 1 to 4 days;
c) cultivating the sebocytes obtained in step b) at the air - liquid interface on said BPER above a "G3F-ERS" culture medium comprising:
(I) epidermal growth factor (EGF),
(II) hydrocortisone, and
(III) insulin,
said G3F-ERS medium further comprising linoleic acid and a PPAR agonist, for a period suitable for allowing differentiation of sebocytes and lipid synthesis, said model of reconstructed sebocyte epithelium being obtained at the end of step c).
6. Method for preparing according to claim 5, wherein the non-immortalized primary sebocytes seeded in step a) are non-immortalized primary sebocytes amplified by the method of amplification according to any one of claims 1 to 5 but in the absence of a ROCK inhibitor.
7. Method for preparing according to claim 5 or 6, wherein the culture medium "G7F-ERS" comprises:
(i) from 1 x10~4 to 2x10"4 M of adenine hydrochloride,
(ii) from 30 to 75 ng/ml of EGF,
(iii) from 0.1 to 1 μg/ml of hydrocortisone,
(iv) from 1 to 10 μg/ml of insulin,
(v) from 5x10"7 to 5x10"6 M of isoproterenol,
(vi) from 1 to 10 μg/ml of transferrin, preferably human transferrin, and
(vii) from 1 x10"9 to 5x10"9 M of triiodothyronine.
8. Method for preparing according to any one of claims 5 to 7, wherein the culture medium "G3F-ERS" comprises:
(I) from 30 to 75 ng/ml of EGF,
(II) from 0.1 to 1 μg/ml of hydrocortisone, and
(III) from 1 to 10 μ9/ιηΙ of insulin,
said G3F-ERS medium further comprising from 1 x10~7 to 2.5x10"5 M of linoleic acid and from 1 x10~6 to 5x10"6 M of a PPAR agonist, said PPAR agonist being preferably the compound GW0742.
9. Model of reconstructed sebocyte epithelium likely to be obtained by the method of preparation according to any one of claims 5 to 8.
10. In vitro method for screening a candidate compound for treating oily and/or glistening skin, comprising putting into contact said candidate compound with the model of reconstructed sebocyte epithelium according to claim 9.
PCT/EP2017/083285 2016-12-22 2017-12-18 Model of reconstructed sebocyte epithelium differentiated from primary human sebocytes WO2018114784A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1663243A FR3061205A1 (en) 2016-12-22 2016-12-22 EPITHELIUM MODEL RECONSTRUCTED SEBOCYTE DIFFERENTIATED FROM PRIMARY HUMAN SEBOCYTES
FR1663243 2016-12-22

Publications (1)

Publication Number Publication Date
WO2018114784A1 true WO2018114784A1 (en) 2018-06-28

Family

ID=58737659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/083285 WO2018114784A1 (en) 2016-12-22 2017-12-18 Model of reconstructed sebocyte epithelium differentiated from primary human sebocytes

Country Status (2)

Country Link
FR (1) FR3061205A1 (en)
WO (1) WO2018114784A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109852576A (en) * 2019-01-07 2019-06-07 施歌 A kind of construction method immortalizing sebocyte cell strain
WO2020079981A1 (en) * 2018-10-17 2020-04-23 株式会社マンダム Method for observing sebaceous gland and utilization thereof
CN114686420A (en) * 2022-04-08 2022-07-01 济南磐升生物技术有限公司 Preparation method and application of 3D epidermis model

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19903920A1 (en) * 1999-02-01 2000-08-10 Ch C Zouboulis Sebocytes, sebocyte cell line and their uses
WO2014055815A1 (en) * 2012-10-05 2014-04-10 Cincinnati Children's Hospital Medical Center Sebocyte cell culturing and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19903920A1 (en) * 1999-02-01 2000-08-10 Ch C Zouboulis Sebocytes, sebocyte cell line and their uses
WO2014055815A1 (en) * 2012-10-05 2014-04-10 Cincinnati Children's Hospital Medical Center Sebocyte cell culturing and methods of use

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BARRAULT ET AL., EXP. DERMATOL., vol. 21, 2012, pages 314 - 316
CHRISTINE BARRAULT ET AL: "Immortalized sebocytes can spontaneously differentiate into a sebaceous-like phenotype when cultured as a 3D epithelium : Letter to the Editor", EXPERIMENTAL DERMATOLOGY, vol. 21, no. 4, 15 April 2012 (2012-04-15), COPENHAGEN; DK, pages 314 - 316, XP055382648, ISSN: 0906-6705, DOI: 10.1111/j.1600-0625.2012.01463.x *
GEORGIOS NIKOLAKIS ET AL: "Ex vivo human skin and SZ95 sebocytes exhibit a homoeostatic interaction in a novel coculture contact model", EXPERIMENTAL DERMATOLOGY, vol. 24, no. 7, 4 July 2015 (2015-07-04), COPENHAGEN; DK, pages 497 - 502, XP055383040, ISSN: 0906-6705, DOI: 10.1111/exd.12712 *
GUY ET AL., J. INVESTIG. DERMATOL., vol. 106, 1996, pages 454 - 460
LO CELSO ET AL., STEM CELLS, vol. 26, 2008, pages 1241 - 1252
LONGQING X ET AL: "ISOLATION OF HUMAN SEBACEOUS GLANDS AND CULTIVATION OF SEBACEOUS GLAND-DERIVED CELLS AS AN IN VITRO MODEL", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NATURE PUBLISHING GROUP, US, vol. 93, no. 3, 1 September 1989 (1989-09-01), pages 315 - 321, XP000885613, ISSN: 0022-202X, DOI: 10.1111/1523-1747.EP12280234 *
LONGQING XIA: "Culture of human sebocytes in vitro", DERMATO-ENDOCRINOLOGY, 1 March 2009 (2009-03-01), United States, pages 92 - 95, XP055250284, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835897/pdf/de0102_0092.pdf> DOI: 10.4161/derm.1.2.8736 *
NIEMANN ET AL., SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, vol. 23, 2012, pages 928 - 936
THIBOUTOT ET AL., J. INVESTIG. DERMATOL., vol. 120, 2003, pages 905 - 914
WOLDOW ET AL., DERMATOLOGY ONLINE JOURNAL, vol. 15, 2009, pages 14
YOSHIDA ET AL., BIOCHEM. BIOPHYS. RES. COM., vol. 438, 2013, pages 640 - 646
ZOUBOULIS ET AL., J. INVESTIG. DERMATOL., vol. 113, 1999, pages 1011 - 1020

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020079981A1 (en) * 2018-10-17 2020-04-23 株式会社マンダム Method for observing sebaceous gland and utilization thereof
US11047849B2 (en) 2018-10-17 2021-06-29 Mandom Corporation Method for observing sebaceous gland and use thereof
CN109852576A (en) * 2019-01-07 2019-06-07 施歌 A kind of construction method immortalizing sebocyte cell strain
CN114686420A (en) * 2022-04-08 2022-07-01 济南磐升生物技术有限公司 Preparation method and application of 3D epidermis model
CN114686420B (en) * 2022-04-08 2023-11-28 济南磐升生物技术有限公司 Preparation method and application of 3D epidermis model

Also Published As

Publication number Publication date
FR3061205A1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
Baglioni et al. Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell
Lu et al. Towards the development of a simplified long‐term organ culture method for human scalp skin and its appendages under serum‐free conditions
Li et al. Adult bone-marrow-derived mesenchymal stem cells contribute to wound healing of skin appendages
JP5484975B2 (en) Biotechnological tissue constructs and methods of generating and using the same
WO2018114784A1 (en) Model of reconstructed sebocyte epithelium differentiated from primary human sebocytes
US8530237B2 (en) Method for culturing animal hepatocyte
EP4123014A1 (en) Cardiac organoid, manufacturing method therefor, and method for evaluating drug toxicity by using same
Eirew et al. Quantitation of human mammary epithelial stem cells with in vivo regenerative properties using a subrenal capsule xenotransplantation assay
JP4822635B2 (en) Artificial hair bulb part, method for producing the same, and drug evaluation method using artificial hair bulb part
Tang et al. Primary culture of human face skin melanocytes for the study of hyperpigmentation
Stuelsatz et al. Isolation, culture, and immunostaining of skeletal muscle myofibers from wildtype and nestin-GFP mice as a means to analyze satellite cells
JP6626245B2 (en) Compositions and methods for making reconstructed skin
Toyoshima et al. Regeneration of a bioengineered 3D integumentary organ system from iPS cells
JP6695964B2 (en) Use of hair matrix cells to prepare microhair follicles
KR102023339B1 (en) Tissue-preserving liquid and tissue-preserving method
Howden et al. Generating kidney organoids from human pluripotent stem cells using defined conditions
Jiang et al. DAPT in the control of human hair follicle stem cell proliferation and differentiation
Robinson et al. In vivo induction of hair growth by dermal cells isolated from hair follicles after extended organ culture
Kazama et al. Histologic and cell kinetic studies of hair loss and subsequent recovery process of human scalp hair follicles grafted onto severe combined immunodeficient mice
JP2017113030A (en) Reconstructed scalp model and process for screening active molecules
Harada et al. Microdissection and isolation of mouse dental epithelial cells of continuously growing mouse incisors
US20150110750A1 (en) Methods for using autologous fibroblasts to alter skin identity
US20200255801A1 (en) Method for the in vitro preparation of dermal papilla and hair follicle equivalents
WO2019092667A1 (en) Method for preparing three-dimensional scaffold-free microtissues for use in the preclinical screening of active substances
EP4249585A1 (en) Heart tissue models, method of producing heart tissue models and uses of heart tissue models

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17835647

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17835647

Country of ref document: EP

Kind code of ref document: A1